AstraZeneca (AZN)

All online trades £12.50 plus an annual Management Fee of £35 & VAT with Selftrade. Apply

2,634.50p
   
  • Change Today:
    -17.00p
  • 52 Week High: 3,194.00p
  • 52 Week Low: 2,543.50p
  • Currency: UK Pounds
  • Shares Issued: 1,266.58m
  • Volume: 2,032,315
  • Market Cap: £33,368m
  • RiskGrade: 102
  • Beta: 0.76

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (16-05-2012)

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 6.7% 6.6%
Div Cover 2.6 2.1
Op Mrgn 38.1% 30.7%
ROCE 84.4%  
Latest F'cast
P/E 5.8 7.1
PEG 0.7 n/a
Pr/Revenue 1.6 1.8
Pr/Book 2.3  
Latest F'cast
Revenue 1.0% -66.1%
PBT 12.7% -71.8%
EPS 8.5% -17.9%
DPS 9.8% -59.8%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-07 29,559.00 7,983.00 438.00¢ 7.9 0.6 +14% 187.00¢ 5.4%
31-Dec-08 31,601.00 8,681.00 510.00¢ 8.8 0.5 +16% 205.00¢ 4.6%
31-Dec-09 32,804.00 10,807.00 632.00¢ 7.3 0.3 +24% 230.00¢ 5.0%
31-Dec-10 33,269.00 10,977.00 671.00¢ 6.9 1.2 +6% 255.00¢ 5.5%
31-Dec-11 33,591.00 12,367.00 728.00¢ 6.5 0.8 +8% 280.00¢ 5.9%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-12 18,110.68 5,552.67 371.64p 7.1 n/a -18% 179.05p 6.6%
31-Dec-13 17,451.92 5,612.27 374.58p 7.0 8.9 +1% 186.67p 6.9%

Copyright © 2012 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Transaction in Own Shares 16-May-2012 07:00 RNS
Transaction in Own Shares 15-May-2012 07:00 RNS
Transaction in Own Shares 14-May-2012 07:00 RNS

AstraZeneca ShareCast News

Wednesday newspaper round-up: Greece, RBS, Astra... 16-May-2012 ShareCast
Broker snap: With new leader, it's Astra's 'time... 04-May-2012 ShareCast
FTSE 100 movers: RBS flying high on results update 04-May-2012 ShareCast

AstraZeneca Top Newspaper Links

AstraZeneca staff find new jobs ahead of plant c... 30-Dec-2011 Telegraph
AstraZeneca back on top with new drug deals 22-Dec-2011 Daily Mail
ASTRAZENECA TURNS TO ASIA 22-Dec-2011 Express & Star

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
27-Apr-12 Buy John Varley 2,653.00p 3,700 £98,161.00
27-Apr-12 Buy Prof Dame Nancy Rothwell 2,652.00p 298 £7,902.96
27-Mar-12 Sell Simon Lowth 0.000p 22,015 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 2,634.50p
Change Today -17.00p
% Change -0.64 %
52 Week High 3,194.00p
52 Week Low 2,543.50p
Volume 2,032,315
Shares Issued 1,266.58m
Market Cap £33,368m
Beta 0.76
RiskGrade 102

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
76.05% above the market average76.05% above the market average76.05% above the market average76.05% above the market average76.05% above the market average
95.65% above the sector average95.65% above the sector average95.65% above the sector average95.65% above the sector average95.65% above the sector average
Price Trend
36.86% below the market average36.86% below the market average36.86% below the market average36.86% below the market average36.86% below the market average
21.43% below the sector average21.43% below the sector average21.43% below the sector average21.43% below the sector average21.43% below the sector average
Income
97.48% above the market average97.48% above the market average97.48% above the market average97.48% above the market average97.48% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
24.65% below the market average24.65% below the market average24.65% below the market average24.65% below the market average24.65% below the market average
91.84% below the sector average91.84% below the sector average91.84% below the sector average91.84% below the sector average91.84% below the sector average

What The Brokers Say

Strong Buy 7
Buy 3
Neutral 19
Sell 7
Strong Sell 6
Total 42
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 15-Feb-12 03-Aug-11
Paid 19-Mar-12 12-Sep-11
Amount 195.00¢ 85.00¢

Trades for 16-May-2012

Time Volume / Share Price
16:51 700 @ 2,633.84p
16:46 63 @ 2,640.00p
16:46 6,913 @ 2,630.57p
16:44 300 @ 2,643.17p
16:44 2,205 @ 2,625.50p

Top of Page